{"success":true,"data":{"pressRelease":{"id":"147964","rtpr_id":"nBw29MS8Da-20260921","ticker":"CURN","exchange":"","all_tickers":["CURN"],"title":"Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)","author":"Business Wire","published_at":"2026-09-21T05:03:00.084Z","article_body":"Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant\nProgress on Corticorelin (C-PTBE-01)\n\nCuratis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and\nservices of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m),\nwith the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and\ncash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m).\nCuratis also advanced its corticorelin (C-PTBE-01) program on multiple levels,\nincluding an exclusive Japan licence with Neupharma and continued\nmanufacturing progress.\n\nBusiness development and finances\n\nNet sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net\nsales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven\nboth by products marketed for some time and by products added to the\ndistribution portfolio in 2025 and 2026.\n\nThe gross contribution from goods and services rose by 32% to CHF 1.8m (H1\n2025: CHF 1.3m); the combined cost base grew by only 9% against net sales\ngrowth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m)\nand other operating expenses 17% to CHF 0.6m (H1 2025: CHF 0.5m). Relatively,\npersonnel expenses fell from 23.0% to 16.0% of net sales, and the gross margin\non goods rose from 20.7% to 22.4%.\n\nCash and cash equivalents rose to CHF 3.6m (31 December 2025: CHF 1.9m),\nreflecting a CHF 3.0 million convertible instrument placed with a strategic\nSwiss investor in May 2026 and converted into equity during the reporting\nperiod (net cash inflow from financing of CHF 3.0m), against cash flow from\noperating activities of CHF -0.9m (H1 2025: CHF -1.1m) and investing\nactivities of CHF -0.4m, reflecting capitalised development expenditure.\n In CHF thousand unless noted                       H1 2026  H1 2025  Change  \n Net sales from goods and services (kCHF)           7'940    5'243    +51%    \n of which net sales from goods                      7'373    5'038    +46%    \n of which net sales from services                   567      205      -       \n Gross contribution from goods and services (kCHF)  1'707    1'292    +32%    \n Operating result (kCHF)                            (401)    (1'291)  +69%    \n Cash and cash equivalents (kCHF)                   3'595¹   1'867²   +92%    \n ¹ 30 June 2026. ² 31 December 2025. For a more detailed discussion, please   \n refer to the half-year report and management discussion and analysis available \n at www.curatis.com                                                           \n (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.curatis.com&esheet=54607792&newsitemid=20260920467749&lan=en-US&anchor=www.curatis.com&index=1&md5=e9f2319ca80326e98be1532ae3b140dc)                             \n .                                                                            \n\n\nCorticorelin / C-PTBE-01\n\nCuratis’ lead product candidate, C-PTBE-01 (corticorelin), is being\ndeveloped to treat peritumoral brain edema (PTBE), affecting more than\n150’000 patients in the US alone, for which the current standard of care,\ncorticosteroids, causes significant side effects and can counteract cancer\nimmunotherapies. Corticorelin is an investigational drug not yet approved for\ntherapeutic use in the United States or elsewhere.\n\nCuratis advanced the corticorelin program on several levels in the first half\nof 2026. In March, the company signed an exclusive licence agreement for\ncorticorelin in Japan with Neupharma, valued at up to CHF 83.5m in upfront and\nmilestone payments plus royalties of up to 20% — Curatis’ first regional\npartnership for the program. As planned, Neupharma met with Japan’s health\nauthority, PMDA, to discuss possible development pathways for that market.\n\nOn the manufacturing side, Curatis received several API batches at a higher\nyield than expected, the technical development for the drug product is on\nschedule and a cell-based potency assay is on track for validation by\nyear-end. Corticorelin, unlike chronic corticosteroid use, may leave immune\nfunction intact. Curatis is actively pursuing this attractive additional field\nof application for the compound.\n\nOutlook\n\nFollowing the strong first-half performance, Curatis confirms its full-year\nguidance of projected revenues of approximately CHF 15m for 2026 (2025: CHF\n10.8m), resulting in a revenue growth of approximately 40% in 2026. The\nGroup’s objective remains a break-even result in 2026.\n\nCuratis plans to meet the FDA in the first quarter of 2027 to finalise the\npivotal Phase 3 study design for corticorelin, following the study design\ndiscussed with the FDA in September 2025. During 2027, the company expects to\ncomplete production of clinical study material and prepare for the study with\na contract research organization, including selection of study centers.\n\nAbout Curatis\n\nCuratis Holding AG is a publicly listed company (CURN.SW) focused on the late\nstage development and commercialization of drugs for rare diseases and\nspecialty care. Curatis has a sales portfolio of 50 products and a pipeline of\norphan and specialty drugs. More information can be found on www.curatis.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.curatis.com&esheet=54607792&newsitemid=20260920467749&lan=en-US&anchor=www.curatis.com&index=2&md5=b98f47953dfa06166cef87092646c4a0)\n.\n\nDisclaimer:\n\nThe information contained in this media release and in any link to our website\nindicated herein is not for use within any country or jurisdiction or by any\npersons where such use would constitute a violation of law. If this applies to\nyou, you are not authorized to access or use any such information.\n\nThis media release contains “forward-looking statements” that are based on\nour current expectations, assumptions, estimates and projections about us and\nour industry. Forward-looking statements include, without limitation, any\nstatement that may predict, forecast, indicate or imply future results,\nperformance or achievements, and may contain the words “may”, “will”,\n“should”, “continue”, “believe”, “anticipate”, “expect”,\n“estimate”, “intend”, “project”, “plan”, “will likely\ncontinue”, “will likely result”, or words or phrases with similar\nmeaning. Undue reliance should not be placed on such statements because, by\ntheir nature, forward-looking statements involve risks and uncertainties,\nincluding, without limitation, economic, competitive, governmental and\ntechnological factors outside of the control of Curatis Group, that may cause\nCuratis’ business, strategy or actual results to differ materially from the\nforward-looking statements (or from past results). For any factors that could\ncause actual results to differ materially from the forward-looking statements\ncontained in this media release, please see the risk factors included in our\nlisting prospectus. Curatis Group undertakes no obligation to publicly update\nor revise any of these forward-looking statements, whether to reflect new\ninformation, future events or circumstances or otherwise. It should further be\nnoted that past performance is not a guide to future performance. Persons\nrequiring advice should consult an independent adviser.\n\nThe information contained in this media release is not an offer to sell or a\nsolicitation of offers to purchase or subscribe for securities. This media\nrelease is not a prospectus within the meaning of the Swiss Financial Services\nAct nor a prospectus under any other applicable laws.\n\nSome financial information in this media release has been rounded and, as a\nresult, the figures shown as totals in this media release may vary slightly\nfrom the exact arithmetic aggregation of the figures that precede them.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260920467749/en/\n(https://www.businesswire.com/news/home/20260920467749/en/)\n\nPatrick Ramsauer, CFO\n\nPhone: +41 61 927 8777\n\nir@curatis.com (mailto:ir@curatis.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw29MS8Da-20260921","title":"Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)","author":"Business Wire","ticker":"CURN","created":"2026-09-21T05:03:00.084Z","tickers":["CURN"],"exchange":"","article_body":"Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant\nProgress on Corticorelin (C-PTBE-01)\n\nCuratis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and\nservices of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m),\nwith the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and\ncash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m).\nCuratis also advanced its corticorelin (C-PTBE-01) program on multiple levels,\nincluding an exclusive Japan licence with Neupharma and continued\nmanufacturing progress.\n\nBusiness development and finances\n\nNet sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net\nsales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven\nboth by products marketed for some time and by products added to the\ndistribution portfolio in 2025 and 2026.\n\nThe gross contribution from goods and services rose by 32% to CHF 1.8m (H1\n2025: CHF 1.3m); the combined cost base grew by only 9% against net sales\ngrowth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m)\nand other operating expenses 17% to CHF 0.6m (H1 2025: CHF 0.5m). Relatively,\npersonnel expenses fell from 23.0% to 16.0% of net sales, and the gross margin\non goods rose from 20.7% to 22.4%.\n\nCash and cash equivalents rose to CHF 3.6m (31 December 2025: CHF 1.9m),\nreflecting a CHF 3.0 million convertible instrument placed with a strategic\nSwiss investor in May 2026 and converted into equity during the reporting\nperiod (net cash inflow from financing of CHF 3.0m), against cash flow from\noperating activities of CHF -0.9m (H1 2025: CHF -1.1m) and investing\nactivities of CHF -0.4m, reflecting capitalised development expenditure.\n In CHF thousand unless noted                       H1 2026  H1 2025  Change  \n Net sales from goods and services (kCHF)           7'940    5'243    +51%    \n of which net sales from goods                      7'373    5'038    +46%    \n of which net sales from services                   567      205      -       \n Gross contribution from goods and services (kCHF)  1'707    1'292    +32%    \n Operating result (kCHF)                            (401)    (1'291)  +69%    \n Cash and cash equivalents (kCHF)                   3'595¹   1'867²   +92%    \n ¹ 30 June 2026. ² 31 December 2025. For a more detailed discussion, please   \n refer to the half-year report and management discussion and analysis available \n at www.curatis.com                                                           \n (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.curatis.com&esheet=54607792&newsitemid=20260920467749&lan=en-US&anchor=www.curatis.com&index=1&md5=e9f2319ca80326e98be1532ae3b140dc)                             \n .                                                                            \n\n\nCorticorelin / C-PTBE-01\n\nCuratis’ lead product candidate, C-PTBE-01 (corticorelin), is being\ndeveloped to treat peritumoral brain edema (PTBE), affecting more than\n150’000 patients in the US alone, for which the current standard of care,\ncorticosteroids, causes significant side effects and can counteract cancer\nimmunotherapies. Corticorelin is an investigational drug not yet approved for\ntherapeutic use in the United States or elsewhere.\n\nCuratis advanced the corticorelin program on several levels in the first half\nof 2026. In March, the company signed an exclusive licence agreement for\ncorticorelin in Japan with Neupharma, valued at up to CHF 83.5m in upfront and\nmilestone payments plus royalties of up to 20% — Curatis’ first regional\npartnership for the program. As planned, Neupharma met with Japan’s health\nauthority, PMDA, to discuss possible development pathways for that market.\n\nOn the manufacturing side, Curatis received several API batches at a higher\nyield than expected, the technical development for the drug product is on\nschedule and a cell-based potency assay is on track for validation by\nyear-end. Corticorelin, unlike chronic corticosteroid use, may leave immune\nfunction intact. Curatis is actively pursuing this attractive additional field\nof application for the compound.\n\nOutlook\n\nFollowing the strong first-half performance, Curatis confirms its full-year\nguidance of projected revenues of approximately CHF 15m for 2026 (2025: CHF\n10.8m), resulting in a revenue growth of approximately 40% in 2026. The\nGroup’s objective remains a break-even result in 2026.\n\nCuratis plans to meet the FDA in the first quarter of 2027 to finalise the\npivotal Phase 3 study design for corticorelin, following the study design\ndiscussed with the FDA in September 2025. During 2027, the company expects to\ncomplete production of clinical study material and prepare for the study with\na contract research organization, including selection of study centers.\n\nAbout Curatis\n\nCuratis Holding AG is a publicly listed company (CURN.SW) focused on the late\nstage development and commercialization of drugs for rare diseases and\nspecialty care. Curatis has a sales portfolio of 50 products and a pipeline of\norphan and specialty drugs. More information can be found on www.curatis.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.curatis.com&esheet=54607792&newsitemid=20260920467749&lan=en-US&anchor=www.curatis.com&index=2&md5=b98f47953dfa06166cef87092646c4a0)\n.\n\nDisclaimer:\n\nThe information contained in this media release and in any link to our website\nindicated herein is not for use within any country or jurisdiction or by any\npersons where such use would constitute a violation of law. If this applies to\nyou, you are not authorized to access or use any such information.\n\nThis media release contains “forward-looking statements” that are based on\nour current expectations, assumptions, estimates and projections about us and\nour industry. Forward-looking statements include, without limitation, any\nstatement that may predict, forecast, indicate or imply future results,\nperformance or achievements, and may contain the words “may”, “will”,\n“should”, “continue”, “believe”, “anticipate”, “expect”,\n“estimate”, “intend”, “project”, “plan”, “will likely\ncontinue”, “will likely result”, or words or phrases with similar\nmeaning. Undue reliance should not be placed on such statements because, by\ntheir nature, forward-looking statements involve risks and uncertainties,\nincluding, without limitation, economic, competitive, governmental and\ntechnological factors outside of the control of Curatis Group, that may cause\nCuratis’ business, strategy or actual results to differ materially from the\nforward-looking statements (or from past results). For any factors that could\ncause actual results to differ materially from the forward-looking statements\ncontained in this media release, please see the risk factors included in our\nlisting prospectus. Curatis Group undertakes no obligation to publicly update\nor revise any of these forward-looking statements, whether to reflect new\ninformation, future events or circumstances or otherwise. It should further be\nnoted that past performance is not a guide to future performance. Persons\nrequiring advice should consult an independent adviser.\n\nThe information contained in this media release is not an offer to sell or a\nsolicitation of offers to purchase or subscribe for securities. This media\nrelease is not a prospectus within the meaning of the Swiss Financial Services\nAct nor a prospectus under any other applicable laws.\n\nSome financial information in this media release has been rounded and, as a\nresult, the figures shown as totals in this media release may vary slightly\nfrom the exact arithmetic aggregation of the figures that precede them.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260920467749/en/\n(https://www.businesswire.com/news/home/20260920467749/en/)\n\nPatrick Ramsauer, CFO\n\nPhone: +41 61 927 8777\n\nir@curatis.com (mailto:ir@curatis.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-21T05:03:00.122544639Z","server_sent_at_ms":1789966980122},"received_at":"2026-09-21T05:03:00.177Z","source_url":"https://www.businesswire.com/news/home/20260920467749/en/"},"analysis":{"id":"136766","press_release_id":"147964","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Cash of CHF 3.6m is thin relative to the cost of a planned pivotal Phase 3 for corticorelin — further financing likely","Neupharma deal value is dominated by contingent milestones ('up to CHF 83.5m'); upfront portion undisclosed","Break-even objective for 2026 leaves little execution margin at current scale"],"eventType":"earnings","narrative":"Curatis reported its strongest half-year to date: H1 2026 net sales from goods and services rose 51% to CHF 7.9m (H1 2025: CHF 5.2m), while the period loss narrowed to CHF -0.4m from CHF -1.2m.\n\nCash and cash equivalents more than doubled to CHF 3.6m, boosted by a CHF 3.0 million convertible instrument placed with a strategic Swiss investor in May 2026 and converted into equity during the reporting period.\n\nThe corticorelin (C-PTBE-01) program for peritumoral brain edema advanced with an exclusive Japan licence to Neupharma worth up to CHF 83.5m in upfront and milestone payments plus royalties of up to 20% — Curatis' first regional partnership for the program. An FDA meeting is planned for Q1 2027 to finalize the pivotal Phase 3 study design.\n\nManagement confirmed full-year 2026 guidance of approximately CHF 15m in revenues (2025: CHF 10.8m, ~40% growth) and reiterated its objective of a break-even result in 2026.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap specialty pharma inflection: 51% H1 growth, confirmed CHF 15m FY26 guide with break-even target, plus a first regional corticorelin licence in Japan."},"keyFigures":{"revenue":"CHF 7.9m","guidance":"FY2026 revenues of approximately CHF 15m confirmed (2025: CHF 10.8m, ~40% growth); objective remains a break-even result in 2026","revenueYoy":"51%","dealValueUsd":"up to CHF 83.5m (Neupharma Japan licence, upfront and milestone payments; CHF not USD)","customDimensions":{"cash":"CHF 3.6m at 30 June 2026 (31 Dec 2025: CHF 1.9m)","net_loss":"CHF -0.4m (H1 2025: CHF -1.2m)","net_sales_goods":"CHF 7.4m, +46%","operating_result":"-401 kCHF (H1 2025: -1,291 kCHF, +69%)","ptbe_us_patients":">150,000","gross_contribution":"CHF 1.8m, +32%","gross_margin_goods":"22.4% (H1 2025: 20.7%)","net_sales_services":"CHF 0.6m (H1 2025: CHF 0.2m)","operating_cash_flow":"CHF -0.9m","convertible_financing":"CHF 3.0m convertible placed with a strategic Swiss investor in May 2026, converted into equity","japan_licence_royalty":"up to 20%","fda_phase3_design_meeting":"Q1 2027"}},"quotedText":"","namedEntities":{"people":[{"name":"Patrick Ramsauer","role":"CFO"}],"products":["C-PTBE-01","corticorelin"],"companies":[{"name":"Curatis Holding AG","ticker":"CURN","relationship":"filer/issuer"},{"name":"Neupharma","relationship":"exclusive Japan licensing partner for corticorelin"},{"name":"PMDA","relationship":"Japanese regulatory authority met by Neupharma on development pathways"},{"name":"FDA","relationship":"US regulatory authority; pivotal Phase 3 design meeting planned Q1 2027"}],"dollarAmounts":[{"amount":"CHF 7.9m","context":"H1 2026 net sales from goods and services"},{"amount":"CHF -0.4m","context":"H1 2026 loss for the period (H1 2025: CHF -1.2m)"},{"amount":"CHF 3.6m","context":"cash and cash equivalents at 30 June 2026"},{"amount":"CHF 3.0 million","context":"convertible instrument placed with a strategic Swiss investor in May 2026"},{"amount":"CHF 83.5m","context":"Neupharma Japan licence value in upfront and milestone payments, plus royalties up to 20%"},{"amount":"CHF 15m","context":"confirmed FY2026 revenue guidance"},{"amount":"CHF 10.8m","context":"2025 full-year revenue"}]},"materialImpact":{"score":3,"reasoning":"Strongest half-year in company history: H1 revenue up 51% to CHF 7.9m, loss narrowed ~69%, cash more than doubled, and the first regional licensing deal for lead asset corticorelin (up to CHF 83.5m) was signed. However, absolute figures are small, no consensus beat data exists, and full-year guidance was confirmed rather than raised."},"tickerRelevance":{"others":[],"primary":"CURN"},"globalImportance":28,"audienceRelevance":12,"eventTypeSecondary":["partnership","guidance_update"],"importanceComponents":{"tickerTier":"micro-cap (SIX Swiss Exchange listed)","eventGravity":"H1 earnings +51% with first regional licensing deal for lead asset","sectorWeight":"specialty pharma / rare disease","issuerAuthored":true,"guidanceDirection":"confirmed, not raised","marketCapAdjustment":"small absolute scale (CHF 7.9m H1 revenue); no consensus comparison available"}},"event_type":"earnings","event_type_secondary":["partnership","guidance_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Curatis reported its strongest half-year to date: H1 2026 net sales from goods and services rose 51% to CHF 7.9m (H1 2025: CHF 5.2m), while the period loss narrowed to CHF -0.4m from CHF -1.2m.\n\nCash and cash equivalents more than doubled to CHF 3.6m, boosted by a CHF 3.0 million convertible instrument placed with a strategic Swiss investor in May 2026 and converted into equity during the reporting period.\n\nThe corticorelin (C-PTBE-01) program for peritumoral brain edema advanced with an exclusive Japan licence to Neupharma worth up to CHF 83.5m in upfront and milestone payments plus royalties of up to 20% — Curatis' first regional partnership for the program. An FDA meeting is planned for Q1 2027 to finalize the pivotal Phase 3 study design.\n\nManagement confirmed full-year 2026 guidance of approximately CHF 15m in revenues (2025: CHF 10.8m, ~40% growth) and reiterated its objective of a break-even result in 2026.","key_figures":{"revenue":"CHF 7.9m","guidance":"FY2026 revenues of approximately CHF 15m confirmed (2025: CHF 10.8m, ~40% growth); objective remains a break-even result in 2026","revenueYoy":"51%","dealValueUsd":"up to CHF 83.5m (Neupharma Japan licence, upfront and milestone payments; CHF not USD)","customDimensions":{"cash":"CHF 3.6m at 30 June 2026 (31 Dec 2025: CHF 1.9m)","net_loss":"CHF -0.4m (H1 2025: CHF -1.2m)","net_sales_goods":"CHF 7.4m, +46%","operating_result":"-401 kCHF (H1 2025: -1,291 kCHF, +69%)","ptbe_us_patients":">150,000","gross_contribution":"CHF 1.8m, +32%","gross_margin_goods":"22.4% (H1 2025: 20.7%)","net_sales_services":"CHF 0.6m (H1 2025: CHF 0.2m)","operating_cash_flow":"CHF -0.9m","convertible_financing":"CHF 3.0m convertible placed with a strategic Swiss investor in May 2026, converted into equity","japan_licence_royalty":"up to 20%","fda_phase3_design_meeting":"Q1 2027"}},"named_entities":{"people":[{"name":"Patrick Ramsauer","role":"CFO"}],"products":["C-PTBE-01","corticorelin"],"companies":[{"name":"Curatis Holding AG","ticker":"CURN","relationship":"filer/issuer"},{"name":"Neupharma","relationship":"exclusive Japan licensing partner for corticorelin"},{"name":"PMDA","relationship":"Japanese regulatory authority met by Neupharma on development pathways"},{"name":"FDA","relationship":"US regulatory authority; pivotal Phase 3 design meeting planned Q1 2027"}],"dollarAmounts":[{"amount":"CHF 7.9m","context":"H1 2026 net sales from goods and services"},{"amount":"CHF -0.4m","context":"H1 2026 loss for the period (H1 2025: CHF -1.2m)"},{"amount":"CHF 3.6m","context":"cash and cash equivalents at 30 June 2026"},{"amount":"CHF 3.0 million","context":"convertible instrument placed with a strategic Swiss investor in May 2026"},{"amount":"CHF 83.5m","context":"Neupharma Japan licence value in upfront and milestone payments, plus royalties up to 20%"},{"amount":"CHF 15m","context":"confirmed FY2026 revenue guidance"},{"amount":"CHF 10.8m","context":"2025 full-year revenue"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-21T05:05:39.750Z","global_importance":28,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap (SIX Swiss Exchange listed)","eventGravity":"H1 earnings +51% with first regional licensing deal for lead asset","sectorWeight":"specialty pharma / rare disease","issuerAuthored":true,"guidanceDirection":"confirmed, not raised","marketCapAdjustment":"small absolute scale (CHF 7.9m H1 revenue); no consensus comparison available"}},"durationMs":159555,"modelName":"glm-5.3-flash"}}